{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:36:07Z","timestamp":1793360167267,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"43","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.1038\/s41388-025-03567-x","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:59:58Z","timestamp":1757501998000},"page":"4114-4129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer"],"prefix":"10.1038","volume":"44","author":[{"given":"Xiaobao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyue","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qitai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenduo","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-3353","authenticated-orcid":false,"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-0690","authenticated-orcid":false,"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"3567_CR1","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008\u201320.","journal-title":"Lancet"},{"key":"3567_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44.","journal-title":"Cell Commun Signal"},{"key":"3567_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","volume":"78","author":"A Henriksen","year":"2019","unstructured":"Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019;78:17\u201330.","journal-title":"Cancer Treat Rev"},{"key":"3567_CR4","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1080\/15548627.2023.2300913","volume":"20","author":"X Zhang","year":"2024","unstructured":"Zhang X, Lao M, Yang H, Sun K, Dong Y, He L, et al. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Autophagy. 2024;20:1314\u201334.","journal-title":"Autophagy"},{"key":"3567_CR5","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1038\/s41388-023-02711-9","volume":"42","author":"Y Duan","year":"2023","unstructured":"Duan Y, Zhang X, Ying H, Xu J, Yang H, Sun K, et al. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Oncogene. 2023;42:2061\u201373.","journal-title":"Oncogene"},{"key":"3567_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05351-1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang T, Ren Y, Yang P, Wang J, Zhou H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13:897.","journal-title":"Cell Death Dis"},{"key":"3567_CR7","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","volume":"13","author":"S Shahvali","year":"2023","unstructured":"Shahvali S, Rahiman N, Jaafari MR, Arabi L. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res. 2023;13:2041\u201356.","journal-title":"Drug Deliv Transl Res"},{"key":"3567_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783\u2013803.","journal-title":"Cancer Metastasis Rev"},{"key":"3567_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MPA.0b013e31816618ce","volume":"37","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, et al. Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma. Pancreas. 2008;37:154\u20138.","journal-title":"Pancreas"},{"key":"3567_CR10","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.3390\/cancers13215501","volume":"13","author":"T MacNeil","year":"2021","unstructured":"MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, et al. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers (Basel). 2021;13:5501.","journal-title":"Cancers (Basel)"},{"key":"3567_CR11","first-page":"1639","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639\u201347.","journal-title":"Clin Cancer Res"},{"key":"3567_CR12","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1158\/0008-5472.CAN-04-0447","volume":"64","author":"S Adams","year":"2004","unstructured":"Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004;64:5471\u201380.","journal-title":"Cancer Res"},{"key":"3567_CR13","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3567_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-615","volume":"12","author":"U Petrausch","year":"2012","unstructured":"Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 2012;12:615.","journal-title":"BMC Cancer"},{"key":"3567_CR15","doi-asserted-by":"publisher","first-page":"e82658","DOI":"10.1371\/journal.pone.0082658","volume":"8","author":"S Gottschalk","year":"2013","unstructured":"Gottschalk S, Yu F, Ji M, Kakarla S, Song XT. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One. 2013;8:e82658.","journal-title":"PLoS One"},{"key":"3567_CR16","doi-asserted-by":"publisher","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-05-2805","volume":"65","author":"J Lee","year":"2005","unstructured":"Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor Immunotherapy Targeting Fibroblast Activation Protein, a Product Expressed in Tumor-Associated Fibroblasts. Cancer Res. 2005;65:11156\u201363.","journal-title":"Cancer Res"},{"key":"3567_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"3567_CR18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125\u201335.","journal-title":"J Exp Med"},{"key":"3567_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00432-013-1547-5","volume":"140","author":"X Li","year":"2014","unstructured":"Li X, Wang Y, Zhao Y, Yang H, Tong A, Zhao C, et al. Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts. J Cancer Res Clin Oncol. 2014;140:271\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3567_CR20","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","volume":"26","author":"M Fabre","year":"2020","unstructured":"Fabre M, Ferrer C, Dom\u00ednguez-Hormaetxe S, Bockorny B, Murias L, Seifert O, et al. OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clinical Cancer Res. 2020;26:3420\u201330.","journal-title":"Clinical Cancer Res"},{"key":"3567_CR21","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/cancers15153886","volume":"15","author":"P Gogia","year":"2023","unstructured":"Gogia P, Ashraf HA-O, Bhasin S, Xu Y. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers (Basel). 2023;15:3886.","journal-title":"Cancers (Basel)"},{"key":"3567_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","volume":"13","author":"W Weng","year":"2023","unstructured":"Weng W, Meng T, Zhao Q, Shen Y, Fu G, Shi J, et al. Antibody\u2013Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023;13:950\u201373.","journal-title":"Cancer Discov"},{"key":"3567_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1155","volume":"13","author":"H Peng","year":"2023","unstructured":"Peng H, Wu X, Liu S, He M, Xie C, Zhong R, et al. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment. Clin Transl Med. 2023;13:e1155.","journal-title":"Clin Transl Med"},{"key":"3567_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","volume":"330","author":"M Kraman","year":"2010","unstructured":"Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827\u201330.","journal-title":"Science"},{"key":"3567_CR25","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","volume":"27","author":"PM Galbo Jr","year":"2021","unstructured":"Galbo PM Jr, Zang X, Zheng D. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. Clin Cancer Res. 2021;27:2636\u201347.","journal-title":"Clin Cancer Res"},{"key":"3567_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0994-2","volume":"18","author":"ME Fiori","year":"2019","unstructured":"Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70.","journal-title":"Mol Cancer"},{"key":"3567_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92232","volume":"2","author":"A Lo","year":"2017","unstructured":"Lo A, Li C-P, Buza EL, Blomberg R, Govindaraju P, Avery D, et al. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight. 2017;2:e92232.","journal-title":"JCI Insight"},{"key":"3567_CR28","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1172\/JCI38988","volume":"119","author":"AM Santos","year":"2009","unstructured":"Santos AM, Jung J, Aziz N, Kissil JL, Pur\u00e9 E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. Journal Clin Investig. 2009;119:3613\u201325.","journal-title":"Journal Clin Investig"},{"key":"3567_CR29","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.3390\/molecules26102943","volume":"26","author":"S Baah","year":"2021","unstructured":"Baah S, Laws M, Rahman KM. Antibody-Drug Conjugates-A Tutorial Review. Molecules. 2021;26:2943.","journal-title":"Molecules"},{"key":"3567_CR30","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3567_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","volume":"21","author":"Y Lin","year":"2019","unstructured":"Lin Y, Li B, Yang X, Cai Q, Liu W, Tian M, et al. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia. 2019;21:1133\u201342.","journal-title":"Neoplasia"},{"key":"3567_CR32","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5:1431\u20138.","journal-title":"JAMA Oncol"},{"key":"3567_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell. 2020;38:788\u2013802.","journal-title":"Cancer Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03567-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03567-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03567-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:02:22Z","timestamp":1760997742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03567-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":33,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025,11,11]]}},"alternative-id":["3567"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03567-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Xun Meng and Weining Weng work in and holds share of Multitude Therapeutics and Abmart Inc. Tao Meng works in MabCare Therapeutics and HySlink Therapeutics. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the First Affiliated Hospital, School of medicine, Zhejiang University (Approval No. 2024-1177). A copy of the ethics committee\u2019s approval letter is available as online supplementary material. Human pancreatic ductal adenocarcinoma (PDAC) specimens were surgically obtained from the Hepatobiliary and Pancreatic Surgery Department. This study protocol received ethical clearance from the Institutional Review Board (IRB) of the First Affiliated Hospital, School of Medicine, Zhejiang University (Approval No. IIT20240569). Written informed consent was acquired from all participating subjects prior to tissue collection. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}